Bicocca Open Archive

Logo unimib boa

Bossi, E., Aroldi, A., Brioschi, F., Steidl, C., Baretta, S., Renso, R., et al. (2020). Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy. AMERICAN JOURNAL OF HEMATOLOGY, 95(12), E319-E321 [10.1002/ajh.25967].

Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy

Bossi E.;Aroldi A.;Steidl C.;Verga L.;Fontana D.;Sharma G. G.;Mologni L.;Piazza R.;Gambacorti Passerini C.
Ultimo
2020
Lettera in rivista
crizotinib, anaplastic lymphoma kinase (ALK) positive, anaplastic large‐cell lymphoma (ALCL), relapsed, refractory
English
2020
95
12
E319
E321
none
Bossi, E., Aroldi, A., Brioschi, F., Steidl, C., Baretta, S., Renso, R., et al. (2020). Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy. AMERICAN JOURNAL OF HEMATOLOGY, 95(12), E319-E321 [10.1002/ajh.25967].
01 - Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/284750
Citazioni
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 20
Social impact